Quantitative intracellular kinetics of HIV type 1

AIDS Research and Human Retroviruses

Volumn 15, Issue 3, 1999, Pages 273-283

  Reddy, Bindu ^a,b   Yin, John ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b EXELIXIS INC   (United States)

^c University of Wisconsin Madison   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; DRUG DESIGN; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; PROVIRUS; T LYMPHOCYTE; VIROGENESIS; VIRUS ASSEMBLY; VIRUS GENE; VIRUS TRANSCRIPTION;

CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; MODELS, BIOLOGICAL; VIRUS REPLICATION;

EID: 0033034676     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311457     Document Type: Article

References (58)

1. Endy D, Kong D, and Yin J: Intracellular kinetics of a growing virus: A genetically structured simulation for bacteriophage T7. Biotech Bioeng 1997;55:375-389.
2. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, and May RM: Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-969.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
4. Bonhoeffer S, May R, Shaw G, and Nowak N: Viral dynamics and drug therapy. Proc Natl Acad Sci USA 1997;94:6971-6976.
5. Palsson B, Keasling JD, and Emerson SG: The regulatory mechanisms of human immunodeficiency virus replication predict multiple expression rates. Proc Natl Acad Sci USA 1990;87:772-776.
6. Hammond BJ: Quantitative study of the control of HIV-1 gene expression. J Theor Biol 1993;163:199-221.
7. Morrow CD, Park J, and Wakefield JK: Viral gene products and replication of the human immunodeficiency type 1 virus. Am J Physiol 1994;266:C1135-C1156.
8. Cullen BR and Greene WC: Regulatory pathways governing HIV-1 replication. Cell 1989;59:423-426.
9. Hope T and Pomerantz RJ: The human immunodeficiency virus type 1 Rev protein: A pivotal protein in the viral life cycle. Curr Top Microbiol Immunol 1995;193:91-105.
10. Henderson LE, Bowers MA, Sowder RCd, Serabyn SA, Johnson DG, Bess JW Jr, Arthur LO, Bryant DK, and Fenselau C: Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: Posttranslational modifications, proteolytic processings, and complete amino acid sequences. J Virol 1992; 66:1856-1865.
11. Ohagen A, Luftig RB, Reicin AS, Yin L, Ikuta K, Kimura T, Goff SP, and Hoglund S: The morphology of the immature HIV-1 virion. Virology 1997;228:112-114.
12. Barbosa P, Charneau P, Dumey N, and Clavel F: Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res Hum Retroviruses 1994;10:53-59.
13. Lewin B: GENES V, 5th Ed. Oxford University Press, New York, 1994.
14. Bird C, Burke J, Gleeson P, and McCluskey J: Expression of human immunodeficiency virus 1 (HIV-1) envelope gene products transcribed from a heterologous promoter. Kinetics of HIV-1 envelope processing in transfected cells. J Biol Chem 1990;265: 19151-19157.
15. Louis JM, Nashed NT, Parris KD, Kimmel AR, and Jerina DM: Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Natl Acad Sci USA 1994;91:7970-7974.
16. Wondrak EM, Nashed NT, Haber MT, Jerina DM, and Louis JM: A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. J Biol Chem 1996;271: 4477-4481.
17. Kay J and Dunn BM: Viral proteinases: Weakness and strength. Biochim Biophys Acta 1990;1048:1-18.
18. Favaro JP and Arrigo SJ: Characterization of Rev function using subgenomic and genomic constructs in T and COS cells. Virology 1997;228:29-38.
19. Pomerantz RJ, Seshamma T, and Trono D: Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: Potential implications for latency. J Virol 1992;66: 1809-1813.
20. m. Biochemistry 1992;31:8221-8228.
21. Abbotts J, Jaju M, and Wilson SH: Thermodynamics of A:G mismatch poly(dG) synthesis by human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 1991;266:3937-3943.
22. Andreadis ST and Palsson BO: Kinetics of retrovirus mediated gene transfer: The importance of intracellular half-life in retroviruses. J Theor Biol 1996;182:1-30.
23. Slice LW, Codner E, Antelman D, Holly M, Wegrzynski B, Wang J, Toome V, Hsu M-C, and Nalin CM: Characterization of recombinant HIV-1 Tat and its interaction with TAR RNA. Biochemistry 1992;31:12062-12068.
24. Okamoto T and Wong-Staal F: Demonstration of virus-specific transcriptional activator(s) in cells infected in HTLV-III by in-vitro cell-free system. Cell 1986;47:29-35.
25. Laspia MF, Wendel W, and Mathews MB: HIV-1 Tat overcomes inefficient transcriptional elongation in vitro. J Mol Biol 1993; 232:732-746.
26. Graeble MA, Churcher MJ, Lowe AD, Gait MJ, and Karn J: Human immunodeficiency virus type 1 transactivator protein Tat, stimulates transcriptional read through of distal terminator sequences in vitro. Proc Natl Acad Sci USA 1993;90:6184-6188.
27. Bohan CA, Kashanchi F, Ensoli B, Luigi B, Boris-Lawrie K, and Brady JN: Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 1992;2:391-407.
28. Daly TJ, Doten RC, Rennert P, Auer M, Jaksche H, Donner A, Fisk G, and Rusche JR: Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element. Biochemistry 1993;32:10479-10505.
29. Darnell JE: Variety in the level of gene control in cells. Nature (London) 1985;342:816-819.
30. Cheng-Kiang S, Nevins JR, and Darnell JE: N-6-Methyl-adenosine in adenovirus type 2 nuclear RNA is conserved in the formation of messenger RNA. J Mol Biol 1979;135:733-752.
31. Schwartz MR, Felber BK, and Pavlakis GN: Discrete RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992;66:150-159.
32. Robert-Guroff M, Popovic M, Gartern S, Markham P, Gallo R, and Reitz MS: Structure and expression of tat, rev and nef-specific transcripts in human immunodeficiency type 1 infected lymphocytes and macrocytes. J Virol 1990;64:3391-3398.
33. Kubota S, Duan L, Furuta RA, Hatanaka M, and Pomerantz RJ: Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol 1996;70: 1282-1287.
34. Otteken A, Earl PL, and Moss B: Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol 1996;70:3407-3415.
35. Burden RL and Faires JD: Numerical Analysis. PWS Publishing Co., Boston, 1993.
36. Modrow S, Kattenbeck B, Von Poblotzki A, Niedrig M, Wagner R, and Wolf H: The Gag proteins of human immunodeficiency virus type 1: Mechanisms of virus assembly and possibilities for interference. Med Microbiol Immunol (Berl) 1994;183:177-194.
37. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, and Swanstrom R: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994;68:8017-8027.
38. Dimitrov DS, Willey RL, Martin MA, and Blumenthal R: Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: Implications for inhibition of virus infection and initial steps of virus entry into cells. Virology 1992;187:398-406.
39. O'Brien WA, Namazi A, Kalhor H, Mao SH, Zack JA, and Chen IS: Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol 1994;68:1258-1263.
40. Pop MP and Biebricher CK: Kinetic analysis of pausing and fidelity of human immunodeficiency virus type 1 reverse transcription. Biochemistry 1996;35:5054-5062.
41. Kim S, Byrn R, Groopman J, and Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency infection; Evidence for differential gene expression. J Virol 1989; 63:3708-3713.
42. Hewlett IK, Geyer SJ, Hawthorne CA, Ruta M, and Epstein JS: Kinetics of early HIV-1 gene expression in infected H9 cells assessed by PCR. Oncogene 1991;6:491-493.
43. Comar M, Marzio G, Pierlanfranco A, and Giacca M: Quantitative dynamics of HIV-1 type-1 expression. AIDS Res Hum Retroviruses 1996;12:117-126.
44. Pellegrino MG, Li G, Potash MJ, and Volsky DJ: Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study. J Biol Chem 1991;266:1783-1788.
45. Bagasra O, Khalili K, Seshamma T, Taylor JP, and Pomerantz RJ: TAR-independent replication of human immunodeficiency virus type 1 in glial cells. J Virol 1992;66:7522-7528.
46. Cavert W, Notermans D, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang Z, Mills R, McDade H, Goudsmit J, Danner SA, and Haase AT: Kinetics of response in lymphoid tissues in antiretroviral therapy in HIV-1 infection. Science 1997; 276:960-964.
47. Li G, Lisziewicz J, Sun D. Zon G, Daefler S, Wong-Staal F, Gallo R, and Klotman M: inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. J Virol 1993;67:6882-6888.
48. Yamada O, Kraus G, Leavitt M, Yu M, and Wong-Staal F: Activity and cleavage of an anti-HIV-1 hairpin ribozyme in human T-cells. Virology 1994;205:121-126.
49. Ojwang J, Hampel A, Looney D, Wong-Staal F, and Rappaport J: Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992;89: 10802-10806.
50. Hartman AF: Antiretroviral therapy. Primary Care 1997;24: 531-560.
51. Johnson VA: Combination therapy for HIV-1 infection-overview: Preclinical and clinical analysis of antiretroviral combinations. Antiviral Res 1996;29:35-39.
52. Gazzard B: What we know so far. AIDS 1996;10(Suppl. 1):S3-S7.
53. Mayers D: Rational approaches to resistance: Nucleoside analogues. AIDS 1996;10(Suppl. 1):S9-S13.
54. Lange JM: Changing therapy in HIV. AIDS 1996;10(Suppl. 1): S27-S30.
55. Kuritzkes DR: Clinical significance of drug resistance in HIV-1 infection. AIDS 1996;10(Suppl. 5):S27-S31.
56. Deminie CA, Bechtold CM, Stock D, Alam M, Djang F, Balch AH, Chou TC, Prichard M, Colonno RJ, and Lin PF: Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996;40:1346-1351.
57. Srivastava KK, Fernandez-Larsson R, Zinkus DM, and Robinson HL: Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: Rate and efficiency of entry, a major determinant of permissiveness. J Virol 1991;65:3900-3902.
58. Perelson A, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, and Ho D: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (London) 1997;387:188-191.